Related references
Note: Only part of the references are listed.Distant Invasive Breast Cancer Recurrence Risk in Human Epidermal Growth Factor Receptor 2-Positive T1a and T1b Node-Negative Localized Breast Cancer Diagnosed From 2000 to 2006: A Cohort From an Integrated Health Care Delivery System
Louis Fehrenbacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study
Ines Vaz-Luis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008
Lindsay M. Morton et al.
BLOOD (2013)
Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
Sandra M. Swain et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Does breast cancer tumor size really matter that much?
Louise Provencher et al.
BREAST (2012)
Myelodysplatic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience.
J. E. Karp et al.
CANCER RESEARCH (2012)
Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Edward H. Romond et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Jersey Chen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
Erin J. Aiello Bowles et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Implications of HER2 Amplification in Small, Node-Negative Breast Cancers: Do Asians Differ?
Fuh Yong Wong et al.
WORLD JOURNAL OF SURGERY (2012)
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study
Ines Vaz-Luis et al.
BREAST CANCER RESEARCH (2012)
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
Heather L. McArthur et al.
CANCER (2011)
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
Lesley A. Smith et al.
BMC CANCER (2010)
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
Yeon Hee Park et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Prognosis and Outcome of Small (≤1 cm), Node-Negative Breast Cancer on the Basis of Hormonal and HER-2 Status
Surabhi Amar et al.
ONCOLOGIST (2010)
Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer
Giuseppe Curigliano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller
Ana M. Gonzalez-Angulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M. Untch et al.
ANNALS OF ONCOLOGY (2008)
FACTORS ASSOCIATED WITH GUIDELINE-CONCORDANT USE OF RADIOTHERAPY AFTER MASTECTOMY IN THE NATIONAL COMPREHENSIVE CANCER NETWORK
Rinaa S. Punglia et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma
Emer O. Hanrahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients
Timothy Kennedy et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC)
E. O. Hanrahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer
Michael J. Hassett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Peripheral neuropathy induced by microtubule-stabilizing agents
JJ Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effect of screening and adjuvant therapy on mortality from breast cancer
DA Berry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The effect of tissue fixation and processing on breast cancer size
B Pritt et al.
HUMAN PATHOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States
M Schootman et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
